Document and Entity Information (USD $)	3 Months Ended
Document and Entity Information (USD $)	Mar. 31, 2011	Apr. 28, 2011
Document and Entity Information [Abstract]
Entity Registrant Name	IDEX CORP /DE/
Entity Central Index Key	0000832101
Document Type	10-Q
Document Period End Date	Mar. 31, 2011
Amendment Flag	false
Document Fiscal Year Focus	2011
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float	$ 2,292,832,953
Entity Common Stock, Shares Outstanding		82,881,231

Condensed Consolidated Balance Sheets (Unaudited) (USD $) In Thousands, unless otherwise specified	3 Months Ended	12 Months Ended
	Mar. 31, 2011	Dec. 31, 2010
Current assets
Cash and cash equivalents	$ 195,548	$ 235,136
Receivables, less allowance for doubtful accounts of $5,255 at March 31,2011 and $5,322 at December 31,2010	242,177	213,553
Inventories - net	215,650	196,546
Other current assets	50,632	47,523
Total current assets	704,007	692,758
Property, plant and equipment - net	199,703	188,562
Goodwill	1,246,258	1,207,001
Intangible assets - net	299,333	281,392
Other noncurrent assets	16,127	11,982
Total assets	2,465,428	2,381,695
Current liabilities
Trade accounts payable	112,906	104,055
Accrued expenses	113,002	117,879
Current portion of long term debt and short term borrowings	102,801	119,445
Dividends payable	0	12,289
Total current liabilities	328,709	353,668
Long-term borrowings	415,383	408,450
Deferred income taxes	153,915	148,534
Other noncurrent liabilities	94,435	95,383
Total liabilities	992,442	1,006,035
Commitment and contingencies
Preferred stock:
Authorized: 5,000,000 shares, $.01 per share par value; Issued: None	0	0
Common stock:
Authorized: 150,000,000 shares, $.01 per share par value; Issued: 85,439,363 shares at March 31,2011 and 84,636,668 shares at December 31, 2010	854	846
Additional paid-in capital	464,131	441,271
Retained earnings	1,052,991	1,005,040
Treasury stock at cost: 2,566,985 shares at both March 31, 2011 and December 31, 2010	(58,848)	(58,788)
Accumulated other comprehensive income (loss)	13,858	(12,709)
Total shareholders' equity	1,472,986	1,375,660
Total liabilities and shareholders' equity	$ 2,465,428	$ 2,381,695

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Mar. 31, 2011	Dec. 31, 2010
Current assets
Allowance for doubtful accounts on receivables	$ 5,255	$ 5,322
Shareholders' equity
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares issued	0	0
Common stock, shares authorized	150,000,000	150,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares issued	85,439,363	84,636,668
Treasury stock, shares	2,566,985	2,566,985

Condensed Consolidated Statements of Operations (Unaudited) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2011	Mar. 31, 2010
Condensed Consolidated Statements of Operations [Abstract]
Net sales	$ 427,089	$ 355,598
Cost of sales	248,389	208,057
Gross profit	178,700	147,541
Selling, general and administrative expenses	100,979	87,781
Restructuring expenses		1,867
Operating income	77,721	57,893
Other income (expense) - net	(907)	254
Interest expense	6,454	3,434
Income before income taxes	70,360	54,713
Provision for income taxes	22,409	18,088
Net income	$ 47,951	$ 36,625
Basic earnings per common share	$ 0.58	$ 0.45
Diluted earnings per common share	$ 0.57	$ 0.45
Share data:
Basic weighted average common shares outstanding	81,430	80,080
Diluted weighted average common shares outstanding	83,248	81,509

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (USD $) In Thousands, unless otherwise specified	Total	Common Stock and Additional Paid-In Capital	Retained Earnings	Cumulative Translation Adjustment	Retirement Benefit Adjustment	Cumulative Unrealized Loss on Derivatives	Treasury Stock
Beginning balance at Dec. 31, 2010	$ 1,375,660	$ 442,117	$ 1,005,040	$ 38,302	$ (30,088)	$ (20,923)	$ (58,788)
Net income	47,951		47,951
Other comprehensive income, net of tax:
Cumulative translation adjustment	24,878			24,878
Amortization of retirement obligations	785				785
Net change on derivatives designated as cash flow hedges	904					904
Other comprehensive income	26,567
Comprehensive income	74,518
Issuance of 818,240 shares of common stock from issuance of unvested shares, exercise of stock options and deferred compensation plans, net of tax benefit	18,019	18,019
Unvested shares surrendered for tax withholding	(60)						(60)
Share-based compensation	4,849	4,849
Ending balance at Mar. 31, 2011	$ 1,472,986	$ 464,985	$ 1,052,991	$ 63,180	$ (29,303)	$ (20,019)	$ (58,848)

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2011	Mar. 31, 2010
Cash flows from operating activities
Net income	$ 47,951	$ 36,625
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	8,324	8,016
Amortization of intangible assets	7,298	6,268
Amortization of debt issuance expenses	251	104
Share-based compensation expense	4,849	4,748
Deferred income taxes	3,011	1,664
Excess tax benefit from share-based compensation	(2,370)	(554)
Changes in:
Receivables	(22,325)	(26,271)
Inventories	(12,875)	(9,496)
Trade accounts payable	6,114	10,320
Accrued expenses	(4,758)	3,417
Other - net	(6,343)	(7,710)
Net cash flows provided by operating activities	29,127	27,131
Cash flows from investing activities
Cash purchases of property, plant and equipment	(11,442)	(7,548)
Acquisition of businesses, net of cash acquired	(50,361)
Other - net	(2,126)
Net cash flows used in investing activities	(63,929)	(7,548)
Cash flows from financing activities
Payments under credit facilities and term loan	(17,983)	(11,077)
Dividends paid	(12,291)	(9,697)
Proceeds from stock option exercises	16,051	1,197
Excess tax benefit from share-based compensation	2,370	554
Other - net	(6)
Net cash flows used in financing activities	(11,859)	(19,023)
Effect of exchange rate changes on cash and cash equivalents	7,073	(2,698)
Net decrease in cash	(39,588)	(2,138)
Cash and cash equivalents at beginning of year	235,136	73,526
Cash and cash equivalents at end of period	195,548	71,388
Cash paid for:
Interest	2,074	3,572
Income taxes	4,712	5,843
Significant non-cash activities:
Contingent consideration for acquisition	2,707
Issuance of unvested shares	$ 269	$ 182

Basis of Presentation and Significant Accounting Policies

3 Months Ended

Mar. 31, 2011

Basis of Presentation and Significant Accounting Policies [Abstract]

Basis of Presentation and Significant Accounting Policies


1.	Basis of Presentation and Significant Accounting Policies

The Condensed Consolidated Financial Statements of IDEX Corporation (“IDEX” or the “Company”) have been prepared in accordance with the instructions to Form 10-Q under the Securities Exchange Act of 1934, as amended. The statements are unaudited but include all adjustments, consisting only of recurring items, except as noted, which the Company considers necessary for a fair presentation of the information set forth herein. The results of operations for the three months ended March 31, 2011 are not necessarily indicative of the results to be expected for the entire year.

The condensed consolidated financial statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010.

Adoption of New Accounting Standards

In October 2009, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2009-13, “Revenue Recognition (Topic 605) — Multiple-Deliverable Revenue Arrangements.” ASU No. 2009-13 addresses the accounting for multiple-deliverable arrangements to enable vendors to account for products or services (deliverables) separately rather than as a combined unit. This guidance establishes a selling price hierarchy for determining the selling price of a deliverable, which is based on: (a) vendor-specific objective evidence; (b) third-party evidence; or (c) estimated selling price. This guidance also eliminates the residual method of allocation and requires that arrangement consideration be allocated at the inception of the arrangement to all deliverables using the relative selling price method. ASU No. 2009-13 is effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010. The adoption of ASU No. 2009-13 effective January 1, 2011 did not have a material impact on the consolidated financial position, results of operations or cash flows of the Company.

In December 2010, the FASB issued ASU No. 2010-29, Business Combinations (Topic 805), “Disclosure of Supplementary Pro Forma Information for Business Combinations” (“ASU No. 2010-29”). ASU No. 2010-29 requires revenues and earnings of the combined entity be disclosed as if the business combination occurred as of the beginning of the comparable prior annual reporting period. The ASU also requires additional disclosures about adjustments included in the reported pro forma revenues and earnings. The Company adopted the provisions of ASU No. 2010-29 prospectively for business combinations for which the acquisition date is on or after January 1, 2011.

Restructuring

3 Months Ended

Mar. 31, 2011

Restructuring [Abstract]

Restructuring


2.	Restructuring

The Company has recorded restructuring costs as a result of cost reduction efforts and facility closings. Accruals have been recorded based on these costs and primarily consist of employee termination benefits. We record expenses for employee termination benefits based on the guidance of Accounting Standards Codification (“ASC”) 420, “Exit or Disposal Cost Obligations.” These expenses were included in Restructuring expenses in the Consolidated Statements of Operations while the related restructuring accruals are included in Accrued expenses in the Consolidated Balance Sheets.

During the three months ended March 31, 2010, the Company recorded $1.9 million of pre-tax restructuring expenses related to its 2009 restructuring initiative for employee severance related to employee reductions across various functional areas as well as facility closures resulting from the Company’s cost savings initiatives.

Pre-tax restructuring expenses, by segment, for the three months ended March 31, 2010 were as follows:


	Severance
	Costs		Exit Costs		Total
	(in thousands)

Fluid & Metering Technologies	$	351	$	18	$	369
Health & Science Technologies		509		54		563
Dispensing Equipment		115		—		115
Fire & Safety/Diversified Products		352		—		352
Corporate office and other		396		72		468

Total restructuring costs	$	1,723	$	144	$	1,867

Restructuring accruals of $2.0 million and $3.5 million as of March 31, 2011 and December 31, 2010, respectively, are reflected in Accrued expenses in the Consolidated Balance Sheets as follows:


	(In thousands)

Balance at January 1, 2011	$	3,543
Payments/Utilization		(1,528	)

Balance at March 31, 2011	$	2,015

The remainder of the restructuring accrual is expected to be paid by the end of 2011.

Acquisitions

3 Months Ended

Mar. 31, 2011

Acquisitions [Abstract]

Acquisitions


3.	Acquisitions

On January 20, 2011, the Company acquired the membership interests of Advanced Thin Films, LLC (“AT Films”). AT Films specializes in optical components and coatings for applications in the fields of scientific research, defense, aerospace, telecommunications and electronics manufacturing. AT Films’ core competence is the design and manufacture of filters, splitters, reflectors and mirrors with the precise physical properties required to support their customers’ most challenging and cutting-edge optical applications. Headquartered in Boulder, Colorado, AT Films has annual revenues of approximately $9.0 million. AT Films operates within the Health & Science Technologies Segment as a part of the IDEX Photonics products platform. The Company acquired AT Films for an aggregate purchase price of $34.5 million, consisting of $31.8 million in cash and contingent consideration valued at approximately $2.7 million. The potential undiscounted amount of all future payments that the Company could be required to pay under the contingent consideration arrangement is between $0 and $3.0 million. Goodwill and intangible assets recognized as part of this transaction were $16.7 million and $11.5 million, respectively. The $16.7 million of goodwill is deductible for tax purposes.

On March 11, 2011, the Company completed the acquisition of Microfluidics International Corporation (“Microfluidics”). Microfluidics is a global leader in the design and manufacture of laboratory and commercial equipment used in the production of micro and nano scale materials for the pharmaceutical and chemical markets. Microfluidics is the exclusive producer of the Microfluidizer^® family of high shear fluid processors for uniform particle size reduction, robust cell disruption and nanoparticle creation. Microfluidics operates within the Health & Science Technologies Segment as a part of the IDEX Pharma platform. The Company acquired Microfluidics for an aggregate purchase price of $18.6 million in cash. Headquartered in Newton, Massachusetts, Microfluidics has annual revenues of approximately $16.0 million. Goodwill and intangible assets recognized as part of this transaction were $4.1 million and $9.7 million, respectively. The $4.1 million of goodwill is not deductible for tax purposes.

The purchase price for AT Films and Microfluidics has been allocated to the assets acquired and liabilities assumed based on estimated fair values at the date of the acquisition. The Company is in the process of obtaining or finalizing appraisals of tangible and intangible assets and it is continuing to evaluate the initial purchase price allocations, as of the acquisition date, which will be adjusted as additional information relative to the fair values of the assets and liabilities of the businesses become known. Accordingly, management has used its best estimate in the initial purchase price allocation as of the date of these financial statements.

The allocation of the acquisition costs to the assets acquired and liabilities assumed, based on their estimated fair values is as follows:


	March 31,
	2011
	In thousands

Current assets, net of cash acquired	$	6,718
Property, plant and equipment		5,586
Goodwill		20,762
Intangible assets		21,152
Other assets		1,939

Total assets acquired		56,157
Total liabilities assumed		(3,089	)

Net assets acquired	$	53,068

Acquired intangible assets consist of patents, trade names, customer relationships and unpatented technology, which are being amortized over a life of 6-15 years. The goodwill recorded for the acquisitions reflects the strategic fit and revenue and earnings growth potential of these businesses.

The Company incurred $1.6 million of acquisition related transaction costs in the first quarter of 2011. These costs were recorded in selling, general and administrative expense and were related to completed transactions, pending transactions and potential transactions, including certain transactions that ultimately were not completed.

Business Segments

3 Months Ended

Mar. 31, 2011

Business Segments [Abstract]

Business Segments


4.	Business Segments

The Company has four reportable business segments: Fluid & Metering Technologies, Health & Science Technologies, Dispensing Equipment and Fire & Safety/Diversified Products.

The Fluid & Metering Technologies Segment designs, produces and distributes positive displacement pumps, flow meters, injectors, and other fluid-handling pump modules and systems and provides flow monitoring and other services for water & wastewater. The Health & Science Technologies Segment designs, produces and distributes a wide range of precision fluidics, rotary lobe pumps, centrifugal and positive displacement pumps, roll compaction and drying systems used in beverage, food processing, pharmaceutical and cosmetics, pneumatic and optical components and sealing solutions, including very high precision, low-flow rate pumping solutions required in analytical instrumentation, clinical diagnostics and drug discovery, high performance molded and extruded, biocompatible medical devices and implantables, air compressors used in medical, dental and industrial applications, and precision gear and peristaltic pump technologies that meet exacting OEM specifications. The Dispensing Equipment Segment produces precision equipment for dispensing, metering and mixing colorants and paints used in a variety of retail and commercial businesses around the world. The Fire & Safety/Diversified Products Segment produces firefighting pumps and controls, rescue tools, lifting bags and other components and systems for the fire and rescue industry, and engineered stainless steel banding and clamping devices used in a variety of industrial and commercial applications.

Information on the Company’s business segments is presented below, based on the nature of products and services offered. The Company evaluates performance based on several factors, of which operating income is the primary financial measure. Intersegment sales are accounted for at fair value as if the sales were to third parties. Certain prior year amounts have been revised to reflect the movement of the Pharma group from the Fluid & Metering Technologies Segment to the Health & Science Technologies Segment.


	Three Months
	Ended
	March 31,
	2011			2010
	(In thousands)

Net sales:
Fluid & Metering Technologies:
External customers	$	195,133		$	166,940
Intersegment sales		140			168

Total group sales		195,273			167,108

Health & Science Technologies:
External customers		133,314			91,751
Intersegment sales		321			1,540

Total group sales		133,635			93,291

Dispensing Equipment:
External customers		31,985			33,538
Intersegment sales		173			16

Total group sales		32,158			33,554

Fire & Safety/Diversified Products:
External customers		66,657			63,369
Intersegment sales		72			32

Total group sales		66,729			63,401

Intersegment elimination		(706	)		(1,756	)

Total net sales	$	427,089		$	355,598

Operating income and income before income taxes:
Fluid & Metering Technologies	$	40,237		$	30,989
Health & Science Technologies		31,114			19,703
Dispensing Equipment		5,639			6,639
Fire & Safety/Diversified Products		15,503			13,071
Corporate office and other		(14,772	)		(12,509	)

Total operating income		77,721			57,893
Interest expense		6,454			3,434
Other income (expense)-net		(907	)		254

Income before income taxes	$	70,360		$	54,713


	March 31,		December 31,
	2011		2010
	(In thousands)

Assets:
Fluid & Metering Technologies	$	1,071,918	$	1,040,601
Health & Science Technologies		789,179		718,884
Dispensing Equipment		233,016		205,540
Fire & Safety/Diversified Products		288,440		278,567
Corporate office and other(1)		82,875		138,103

Total assets	$	2,465,428	$	2,381,695


(1)		Includes intersegment eliminations.

Earnings Per Common Share

3 Months Ended

Mar. 31, 2011

Earnings Per Common Share [Abstract]

Earnings Per Common Share


5.	Earnings Per Common Share

Earnings per common share (“EPS”) are computed by dividing net income by the weighted average number of shares of common stock (basic) plus common stock equivalents outstanding (diluted) during the period. Common stock equivalents consist of stock options, which have been included in the calculation of weighted average shares outstanding using the treasury stock method, unvested shares, and shares issuable in connection with certain deferred compensation agreements (“DCUs”).

ASC 260 “Earnings Per Share”, (“ASC 260”) concludes that all outstanding unvested share-based payment awards that contain rights to nonforfeitable dividends participate in undistributed earnings with common shareholders. If awards are considered participating securities, the Company is required to apply the two-class method of computing basic and diluted earnings per share. The Company has determined that its outstanding unvested shares are participating securities. Accordingly, earnings per common share are computed using the two-class method prescribed by ASC 260. Net income attributable to common shareholders was reduced by $0.4 million for both the three months ended March 31, 2011 and 2010.

Basic weighted average shares reconciles to diluted weighted average shares as follows:


	Three Months
	Ended March 31,
	2011		2010
	(In thousands)

Basic weighted average common shares outstanding		81,430		80,080
Dilutive effect of stock options, unvested shares, and DCUs		1,818		1,429

Diluted weighted average common shares outstanding		83,248		81,509

Options to purchase approximately 0.7 million and 3.0 million shares of common stock as of March 31, 2011 and 2010, respectively, were not included in the computation of diluted EPS because the exercise price was greater than the average market price of the Company’s common stock and, therefore, the effect of their inclusion would be antidilutive.

Inventories

3 Months Ended

Mar. 31, 2011

Inventories [Abstract]

Inventories


6.	Inventories

The components of inventories as of March 31, 2011 and December 31, 2010 were:


	March 31,		December 31,
	2011		2010
	(In thousands)

Raw materials and component parts	$	142,106	$	126,901
Work-in-process		26,077		23,164
Finished goods		47,467		46,481

Total	$	215,650	$	196,546

Inventories are stated at the lower of cost or market. Cost, which includes material, labor, and factory overhead, is determined on a FIFO basis.

Goodwill and Intangible Assets

3 Months Ended

Mar. 31, 2011

Goodwill and Intangible Assets [Abstract]

Goodwill and Intangible Assets


7.	Goodwill and Intangible Assets

The changes in the carrying amount of goodwill for the three months ended March 31, 2011, by reportable business segment, were as follows:


	Fluid &		Health &				Fire & Safety/
	Metering		Science		Dispensing		Diversified
	Technologies		Technologies		Equipment		Products		Total
	(In thousands)

Balance at December 31, 2010(1)	$	523,766	$	439,415	$	98,780	$	145,040	$	1,207,001
Acquisition adjustments		—		270		—		—		270
Foreign currency translation		7,739		2,002		4,920		3,564		18,225
Acquisitions		—		20,762		—		—		20,762

Balance at March 31, 2011	$	531,505	$	462,449	$	103,700	$	148,604	$	1,246,258


(1)		Revised to reflect the movement of the Pharma group from the Fluid & Metering Technologies Segment to the Health & Science Technologies Segment.

ASC 350 “Goodwill and Other Intangible Assets” requires that goodwill be tested for impairment at the reporting unit level on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. Annually on October 31, goodwill and other acquired intangible assets with indefinite lives are tested for impairment. The Company concluded that the fair value of each of the reporting units was in excess of the carrying value as of October 31, 2010. The Company did not consider there to be any triggering event that would require an interim impairment assessment, therefore none of the goodwill or other acquired intangible assets with indefinite lives were tested for impairment during the three months ended March 31, 2011.

The following table provides the gross carrying value and accumulated amortization for each major class of intangible asset at March 31, 2011 and December 31, 2010:


	At March 31, 2011									At December 31, 2010
	Gross							Weighted		Gross
	Carrying		Accumulated					Average		Carrying		Accumulated
	Amount		Amortization			Net		Life		Amount		Amortization			Net
	(In thousands)

Amortizable intangible assets:
Patents	$	10,387	$	(5,260	)	$	5,127		11	$	9,906	$	(5,052	)	$	4,854
Trade names		74,352		(15,153	)		59,199		15		69,043		(13,769	)		55,274
Customer relationships		184,085		(53,092	)		130,993		11		169,065		(47,686	)		121,379
Non-compete agreements		4,097		(3,616	)		481		4		4,087		(3,501	)		586
Unpatented technology		48,869		(10,706	)		38,163		13		43,206		(9,407	)		33,799
Other		6,058		(2,788	)		3,270		10		5,957		(2,557	)		3,400

Total amortizable intangible assets		327,848		(90,615	)		237,233				301,264		(81,972	)		219,292
Banjo trade name		62,100		—			62,100				62,100		—			62,100

	$	389,948	$	(90,615	)	$	299,333			$	363,364	$	(81,972	)	$	281,392

The Banjo trade name is an indefinite lived intangible asset which is tested for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the asset might be impaired.

- Definition

Discloses the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain or loss on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. This element may be used as a single block of text to include the entire intangible asset disclosure including data and tables.

+ References+ Details

Accrued Expenses

3 Months Ended

Mar. 31, 2011

Accrued Expenses [Abstract]

Accrued Expenses


8.	Accrued Expenses

The components of accrued expenses as of March 31, 2011 and December 31, 2010 were:


	March 31,		December 31,
	2011		2010
	(In thousands)

Payroll and related items	$	43,114	$	46,937
Management incentive compensation		5,143		19,985
Income taxes payable		18,310		6,126
Deferred income taxes		295		723
Insurance		5,766		5,544
Warranty		4,142		3,831
Deferred revenue		8,115		7,172
Restructuring		2,015		3,543
Interest rate exchange agreement		1,723		2,328
Liability for uncertain tax positions		1,480		1,647
Accrued interest		5,230		1,101
Other		17,669		18,942

Total accrued expenses	$	113,002	$	117,879

Borrowings

3 Months Ended

Mar. 31, 2011

Borrowings [Abstract]

Borrowings


10.	Borrowings

Borrowings at March 31, 2011 and December 31, 2010 consisted of the following:


	March 31,		December 31,
	2011		2010
	(In thousands)

Credit Facility	$	19,238	$	27,842
Term Loan		82,000		90,000
2.58% Senior Euro Notes		114,194		107,341
4.5% Senior Notes		298,459		298,427
Other borrowings		4,293		4,285

Total borrowings		518,184		527,895
Less current portion		102,801		119,445

Total long-term borrowings	$	415,383	$	408,450

The Company maintains a $600.0 million unsecured domestic, multi-currency bank revolving credit facility (“Credit Facility”), which expires on December 21, 2011. In 2008, the Credit Facility was amended to allow the Company to designate certain foreign subsidiaries as designated borrowers. Upon approval from the lenders, the designated borrowers were allowed to receive loans under the Credit Facility. A designated borrower sublimit was established as the lesser of the aggregate commitments or $100.0 million. As of the amendment date, Fluid Management Europe B.V., (“FME”) was approved by the lenders as a designated borrower. On March 16, 2010, IDEX UK Ltd. (“IDEX UK”) was also approved by the lenders as a designated borrower. FME had no borrowings under the Credit Facility at March 31, 2011. IDEX UK’s borrowings under the Credit Facility, which are included within the current portion of long term debt at March 31, 2011, were £12.0 million ($19.2 million). As IDEX UK’s borrowings under the Credit Facility are British Pound denominated and the cash flows that will be used to make payments of principal and interest are predominately generated in British Pound, the Company does not anticipate any significant foreign exchange gains or losses in servicing this debt.

At March 31, 2011, there was $19.2 million outstanding under the Credit Facility. The net available borrowing under the Credit Facility at March 31, 2011, was approximately $580.8 million. Interest is payable quarterly on the outstanding borrowings at the bank agent’s reference rate. Interest on borrowings, based on LIBOR plus an applicable margin, is payable on the maturity date of the borrowing, or quarterly from the effective date for borrowings exceeding three months. The applicable margin is based on the Company’s senior, unsecured, long-term debt rating and can range from 24 basis points to 50 basis points. Based on the Company’s credit rating at March 31, 2011, the applicable margin was 40 basis points. An annual Credit Facility fee, also based on the Company’s credit rating, is currently 10 basis points and is payable quarterly.

On April 18, 2008, the Company completed a $100.0 million unsecured senior bank term loan agreement (“Term Loan”), with covenants consistent with the Credit Facility and a maturity on December 21, 2011. At March 31, 2011, there was $82.0 million outstanding under the Term Loan, which was included within the current portion of long term debt. Interest under the Term Loan is based on the bank agent’s reference rate or LIBOR plus an applicable margin and is payable at the end of the selected interest period, but at least quarterly. The applicable margin is based on the Company’s senior, unsecured, long-term debt rating and can range from 45 to 100 basis points. Based on the Company’s current debt rating, the applicable margin is 80 basis points.

The Company currently maintains an interest rate exchange agreement related to the Term Loan which expires in December 2011. This interest rate exchange agreement has a current notional amount of $82.0 million and effectively converted $100.0 million of floating-rate debt into fixed-rate debt at an interest rate of 4.00%. The fixed rate is comprised of the fixed rate on the interest rate exchange agreement and the Company’s current margin of 80 basis points on the Term Loan.

On June 9, 2010, the Company completed a private placement of €81.0 million ($96.8 million) aggregate principal amount of 2.58% Series 2010 Senior Euro Notes due June 9, 2015 (“2.58% Senior Euro Notes”) pursuant to a Master Note Purchase Agreement, dated June 9, 2010 (the “Purchase Agreement”). The Purchase Agreement provides for the issuance of additional series of notes in the future, provided that the aggregate principal amount outstanding under the agreement at any time does not exceed $750.0 million. The 2.58% Senior Euro Notes bear interest at a rate of 2.58% per annum and will mature on June 9, 2015. The 2.58% Senior Euro Notes are unsecured obligations of the Company and rank pari passu in right of payment with all of the Company’s other senior debt. The Company may at any time prepay all or any portion of the 2.58% Senior Euro Notes; provided that any such portion is greater than 5% of the aggregate principal amount of Notes then outstanding under the Purchase Agreement. In the event of a prepayment, the Company will pay an amount equal to par plus accrued interest plus a make-whole premium. The Purchase Agreement contains certain covenants that restrict the Company’s ability to, among other things, transfer or sell assets, create liens and engage in certain mergers or consolidations. In addition, the Company must comply with a leverage ratio and interest coverage ratio as set forth in the Purchase Agreement. The Purchase Agreement provides for customary events of default. In the case of an event of default arising from specified events of bankruptcy or insolvency, all outstanding 2.58% Senior Euro Notes will become due and payable immediately without further action or notice. In the case of payment events of defaults, any holder of the 2.58% Senior Euro Notes affected thereby may declare all the 2.58% Senior Euro Notes held by it due and payable immediately. In the case of any other event of default, a majority of the holders of the 2.58% Senior Euro Notes may declare all the 2.58% Senior Euro Notes to be due and payable immediately. The Company used a portion of the proceeds from the private placement to pay down existing debt outstanding under the Credit Facility that had previously been denominated in Euros, with the remainder being available for ongoing business activities.

On December 6, 2010, the Company completed a public offering of $300.0 million 4.5% senior notes due December 15, 2020 (“4.5% Senior Notes”). The net proceeds from the offering of approximately $295.7 million, after deducting the $1.6 million issuance discount, the $1.9 million underwriting commission and estimated offering expenses of approximately $0.8 million, was used to repay $250.0 million of outstanding indebtedness under the Credit Facility. The balance of the net proceeds was used for general corporate purposes. The 4.5% Senior Notes bear interest at a rate of 4.5% per annum, which is payable semi-annually in arrears on each June 15 and December 15, beginning June 15, 2011. The Company may redeem all or part of the 4.5% Senior Notes at any time prior to maturity at the redemption prices set forth in the Note Indenture (“Indenture”) governing the 4.5% Senior Notes. The Company may issue additional debt from time to time pursuant to the Indenture. The Indenture and 4.5% Senior Notes contain covenants that limit the Company’s ability to, among other things, incur certain liens securing indebtedness, engage in certain sale-leaseback transactions, and enter into certain consolidations, mergers, conveyances, transfers or leases of all or substantially all the Company’s assets. The terms of the 4.5% Senior Notes also require the Company to make an offer to repurchase 4.5% Senior Notes upon a change of control triggering event (as defined in the Indenture) at a price equal to 101% of their principal amount plus accrued and unpaid interest if any.

On April 15, 2010, the Company entered into a forward starting interest rate contract with a notional amount of $300.0 million with a settlement date in December 2010. This contract was entered into in anticipation of the issuance of the 4.5% Senior Notes and was designed to lock in the market interest rate as of April 15, 2010. The Company settled this interest rate contract in December 2010, resulting in a $31.0 million payment. The $31.0 million is being amortized into interest expense over the 10 year term of the 4.5% Senior Notes, which results in an effective interest rate of 5.8%.

There are two key financial covenants that the Company is required to maintain in connection with the Credit Facility, Term Loan, and 2.58% Senior Euro Notes. There are no financial covenants relating to the 4.5% Senior Notes. The most restrictive financial covenants under these debt instruments require a minimum interest coverage ratio (operating cash flow to interest) of 3.0 to 1 and a maximum leverage ratio (outstanding debt to operating cash flow) of 3.25 to 1. At March 31, 2011, the Company was in compliance with both of these financial covenants.

Derivative Instruments

3 Months Ended

Mar. 31, 2011

Derivative Instruments [Abstract]

Derivative Instruments


11.	Derivative Instruments

The Company enters into cash flow hedges to reduce the exposure to variability in certain expected future cash flows. The type of cash flow hedges the Company enters into includes foreign currency contracts and interest rate exchange agreements that effectively convert a portion of floating-rate debt to fixed-rate debt and are designed to reduce the impact of interest rate changes on future interest expense.

The effective portion of gains or losses on interest rate exchange agreements is reported in accumulated other comprehensive income (loss) in shareholders’ equity and reclassified into net income in the same period or periods in which the hedged transaction affects net income. The remaining gain or loss in excess of the cumulative change in the present value of future cash flows or the hedged item, if any, is recognized into net income during the period of change.

Fair values relating to derivative financial instruments reflect the estimated amounts that the Company would receive or pay to sell or buy the contracts based on quoted market prices of comparable contracts at each balance sheet date.

At March 31, 2011, the Company had one interest rate exchange agreement. The interest rate exchange agreement, expiring in December 2011, with a current notional amount of $82.0 million, effectively converted $100.0 million of floating-rate debt into fixed-rate debt at an interest rate of 4.00%. The fixed rate consists of the fixed rate on the interest rate exchange agreements and the Company’s current margin of 80 basis points on the Term Loan.

Approximately $5.2 million of the gross amount included in accumulated other comprehensive income (loss) in shareholders’ equity at March 31, 2011 will be recognized to net income over the next 12 months as the underlying hedged transactions are realized. The $5.2 million is comprised of $1.7 million from the interest rate agreement and $3.5 million from the forward starting interest rate contract settled in December 2010 (see Note 10).

At March 31, 2011, the Company had foreign currency exchange contracts with an aggregate notional amount of $1.0 million to manage its exposure to fluctuations in foreign currency exchange rates. The change in fair market value of these contracts for the three months ended March 31, 2011 was immaterial.

The following table sets forth the fair value amounts of derivative instruments held by the Company as of March 31, 2011 and December 31, 2010:


	Fair Value Assets (Liabilities)
	March 31,			December 31,
	2011			2010			Balance Sheet Caption
	(In thousands)

Interest rate agreements	$	(1,723	)	$	(2,328	)	Accrued expenses
Foreign exchange contracts		99			176		Other current assets

The following table summarizes the gain (loss) recognized and the amounts and location of income (expense) and gain (loss) reclassified into income for interest rate contracts and foreign currency contracts for March 31, 2011 and 2010:


						Expense
	Gain (Loss) Recognized in					and Gain
	Other Comprehensive					Reclassified into
	Income					Income
	Three Months Ended March 31,											Income
	2011			2010		2011			2010			Statement Caption
	(In thousands)

Interest rate agreements	$	955		$	116	$	(1,560	)	$	(2,326	)	Interest expense
Foreign exchange contracts		(55	)		—		120			—		Sales

Fair Value Measurements

3 Months Ended

Mar. 31, 2011

Fair Value Measurements [Abstract]

Fair Value Measurements


12.	Fair Value Measurements

ASC 820 “Fair Value Measurements and Disclosures” defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The standard utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:


	•	Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

	•	Level 2: Inputs, other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

	•	Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.

The following table summarizes the basis used to measure the Company’s financial assets and (liabilities) at fair value on a recurring basis in the balance sheet at March 31, 2011 and December 31, 2010:


	Basis of Fair Value Measurements
	Balance at
	March 31, 2011			Level 1		Level 2			Level 3
	(In thousands)

Money market investment	$	41,868		$	41,868	$	—		$	—
Available for sale securities		2,126			2,126		—			—
Contingent consideration		(2,707	)		—		—			(2,707	)
Interest rate agreements		(1,723	)		—		(1,723	)		—
Foreign currency contracts		99			—		99			—


	Basis of Fair Value Measurements
	Balance at
	December 31, 2010			Level 1		Level 2			Level 3
	(In thousands)

Money market investment	$	96,730		$	96,730	$	—		$	—
Interest rate agreements		(2,328	)		—		(2,328	)		—
Foreign currency contracts		176			—		176			—

There were no transfers of assets or liabilities between Level 1 and Level 2 during the first three months in 2011 or 2010.

In determining the fair value of the Company’s interest rate exchange agreement derivatives, the Company used a present value of expected cash flows based on market observable interest rate yield curves commensurate with the term of each instrument and the credit default swap market to reflect the credit risk of either the Company or the counterparty.

In determining the fair value of the Company’s contingent consideration, the Company used a probability weighted estimate based on an independent appraisal, adjusted for the time value of money.

The carrying value of our cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates their fair values because of the short term nature of these instruments. At March 31, 2011, the fair value of our Credit Facility, Term Loan, 2.58% Senior Euro Notes and 4.5% Senior Notes, based on quoted market prices and current market rates for debt with similar credit risk and maturity, was approximately $502.4 million compared to the carrying value of $513.9 million.

- Definition

This item represents the complete disclosure regarding the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments, assets, and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the Company is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risk is are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References+ Details

Share-Based Compensation

3 Months Ended

Mar. 31, 2011

Share-Based Compensation [Abstract]

Share-Based Compensation


14.	Share-Based Compensation

During the three months ended March 31, 2011, the Company granted approximately 0.7 million stock options and 0.2 million unvested shares, respectively. During the three months ended March 31, 2010, the Company granted approximately 0.9 million stock options and 0.2 million unvested shares, respectively.

Weighted average option fair values and assumptions for the period specified are disclosed in the following table:


	Three Months Ended March 31,
	2011	2010

Weighted average fair value of grants	$12.34	$9.55
Dividend yield	1.46%	1.50%
Volatility	32.76%	33.45%
Risk-free forward interest rate	0.28% - 5.62%	0.32% - 5.69%
Expected life (in years)	6.18	5.98

The assumptions are as follows:


	•	The Company estimated volatility using its historical share price performance over the contractual term of the option.

	•	The Company uses historical data to estimate the expected life of the option. The expected life assumption for the three months ended March 31, 2011 and 2010 is an output of the Binomial lattice option-pricing model, which incorporates vesting provisions, rate of voluntary exercise and rate of post-vesting termination over the contractual life of the option to define expected employee behavior.

	•	The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual life of the option. For the three months ended March 31, 2011 and 2010, we present the range of risk-free one-year forward rates, derived from the U.S. treasury yield curve, utilized in the Binomial lattice option-pricing model.


	•	The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the contractual life of the option.

The Company’s policy is to recognize compensation cost on a straight-line basis over the requisite service period for the entire award. Additionally, the Company’s general policy is to issue new shares of common stock to satisfy stock option exercises or grants of unvested shares.

Total compensation cost for the stock options is as follows:


	Three Months
	Ended
	March 31,
	2011			2010
	(In thousands)

Cost of goods sold	$	235		$	258
Selling, general and administrative expenses		2,053			1,957

Total expense before income taxes		2,288			2,215
Income tax benefit		(736	)		(700	)

Total expense after income taxes	$	1,552		$	1,515

Total compensation cost for the unvested shares is as follows:


	Three Months
	Ended
	March 31,
	2011			2010
	(In thousands)

Cost of goods sold	$	148		$	127
Selling, general and administrative expenses		2,413			2,406

Total expense before income taxes		2,561			2,533
Income tax benefit		(504	)		(567	)

Total expense after income taxes	$	2,057		$	1,966

Classification of stock compensation cost within the Consolidated Statements of Operations is consistent with classification of cash compensation for the same employees and $0.1 million of compensation cost was capitalized as part of inventory for the three months ended March 31, 2011 and 2010.

As of March 31, 2011, there was $15.2 million of total unrecognized compensation cost related to stock options that is expected to be recognized over a weighted-average period of 1.5 years, and $14.4 million of total unrecognized compensation cost related to unvested shares that is expected to be recognized over a weighted-average period of 1.2 years.

Retirement Benefits

3 Months Ended

Mar. 31, 2011

Retirement Benefits [Abstract]

Retirement Benefits


15.	Retirement Benefits

The Company sponsors several qualified and nonqualified defined benefit and defined contribution pension plans and other postretirement plans for its employees. The following tables provide the components of net periodic benefit cost for its major defined benefit plans and its other postretirement plans.


	Pension Benefits
	Three Months Ended March 31,
	2011						2010
	U.S.			Non-U.S.			U.S.			Non-U.S.
	(In thousands)

Service cost	$	460		$	202		$	469		$	184
Interest cost		1,132			574			1,140			552
Expected return on plan assets		(1,198	)		(277	)		(1,108	)		(83	)
Net amortization		1,081			110			1,127			76

Net periodic benefit cost	$	1,475		$	609		$	1,628		$	729


	Other Benefits
	Three Months Ended
	March 31,
	2011			2010
	(In thousands)

Service cost	$	173		$	130
Interest cost		259			259
Net amortization		(39	)		(99	)

Net periodic benefit cost	$	393		$	290

The Company previously disclosed in its financial statements for the year ended December 31, 2010, that it expected to contribute approximately $7.9 million to its pension plans and $1.0 million to its other postretirement benefit plans in 2011. As of March 31, 2011, $3.3 million of contributions have been made to the pension plans and $0.1 million have been made to its other postretirement benefit plans. The Company presently anticipates contributing up to an additional $5.5 million in 2011 to fund its pension plans and other postretirement benefit plans.

- Definition

Description containing the entire pension and other postretirement benefits disclosure as a single block of text.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 158

-Paragraph 7, 21, 22

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 132R

-Paragraph 5, 6, 7, 8

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 132R

-Paragraph 8

-Subparagraph m

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 106

-Paragraph 518

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 87

-Paragraph 264

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 132R

-Paragraph 5

-Subparagraph b

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 132R

-Paragraph 5

-Subparagraph a

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 132R

-Paragraph 5

-Subparagraph h

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 132R

-Paragraph 5

-Subparagraph q

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS106-2

-Paragraph 20, 21, 22

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 03-2

-Paragraph 8

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 30

-Paragraph 26

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Implementation Guide (Q and A)

-Number FAS88

-Paragraph 63

+ Details

Income Taxes

3 Months Ended

Mar. 31, 2011

Income Taxes [Abstract]

Income Taxes


17.	Income Taxes

The Company’s provision for income taxes is based upon estimated annual tax rates for the year applied to federal, state and foreign income. The provision for income taxes increased to $22.4 million in the first quarter of 2011 from $18.1 million in the first quarter of 2010. The effective tax rate decreased to 31.8% for the first quarter of 2011 compared to 33.1% in the first quarter of 2010 due to the mix of global pre-tax income among jurisdictions.

The Company and its subsidiaries file U.S. federal income tax returns and various tax returns in state and foreign jurisdictions. Due to the potential for resolution of federal, state and foreign examinations, and the expiration of various statutes of limitation, it is reasonably possible that the Company’s gross unrecognized tax benefits balance may change within the next twelve months by a range of zero to $1.1 million.

Comprehensive Income

3 Months Ended

Mar. 31, 2011

Comprehensive Income [Abstract]

Comprehensive Income


18.	Comprehensive Income

The components of comprehensive income are as follows:


	Three Months
	Ended
	March 31,
	2011		2010
	(In thousands)

Net income	$	47,951	$	36,625
Other comprehensive income:
Unrealized gains on derivatives, net of tax		904		1,575
Pension and other post-retirement plans, net of tax		785		743
Cumulative translation adjustment		24,878		(22,641	)

Comprehensive income	$	74,518	$	16,302

Foreign currency translation adjustments are generally not adjusted for income taxes as they relate to indefinite investments in non-U.S. subsidiaries.

- Definition

This label may include the following: 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. Components of comprehensive income include: (1) foreign currency translation adjustments; (2) gains and losses on foreign currency transactions that are designated as, and are effective as, economic hedges of a net investment in a foreign entity; (3) gains and losses on intercompany foreign currency transactions that are of a long-term-investment nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements; (4) change in the market value of a futures contract that qualifies as a hedge of an asset reported at fair value; (5) unrealized holding gains and losses on available-for-sale securities and that resulting from transfers of debt securities from the held-to-maturity category to the available-for-sale category; (6) a net loss recognized as an additional pension liability not yet recognized as net periodic pension cost; and (7) the net gain or loss and net prior service cost or credit for pension plans and other postretirement benefit plans.

+ References+ Details

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parenthetical)	3 Months Ended
	Mar. 31, 2011
Issuance of common stock from unvested shares, exercise of stock options and deferred compensation plans, net of tax	818,420
Common Stock and Additional Paid-In Capital
Issuance of common stock from unvested shares, exercise of stock options and deferred compensation plans, net of tax	818,240